Hansoh Pharmaceutical (03692): Four Innovative Drugs Renewed in China's 2024 National Reimbursement Drug List

Hansoh Pharma (03692) announced that the following four innovative drugs of the group have been renewed and included in the "National Basic Medical Insurance, Work-related Injury Insurance, and Maternity Insurance Drug Catalogue (2024)" published by the National Healthcare Security Administration and the Ministry of Human Resources and Social Security of China. The 2024 National Medical Insurance Catalogue will be officially implemented on January 1, 2025.

1. Almonertinib Mesylate Tablets (trade name: Amilevo®), independently developed by Hansoh Pharmaceutical Group, is the first third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) drug in China. Both of its approved indications have been renewed and included in the 2024 National Reimbursement Drug List (NRDL) of China:

• First-line treatment for adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring EGFR exon 19 deletions or exon 21 (L858R) substitution mutations.

• Treatment of adult patients with locally advanced or metastatic NSCLC who have disease progression during or after prior EGFR-TKI therapy and whose tumors are confirmed to harbor the EGFR T790M mutation.

2. Flumatinib Mesylate Tablets (Trade Name: HANSOH XINFU®), is the first self-developed novel second-generation Bcr-Abl TKI in China by Hansoh Pharmaceutical Group Company Limited, used for treating adult patients with Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in the chronic phase.

3. Inebilizumab Injection (trade name: Xinyue®) is a CD19-targeted B-cell depleting antibody, used for adult patients with neuromyelitis optica spectrum disorder (NMOSD) who are positive for anti-aquaporin-4 (AQP4) antibodies.

4. Polyethylene Glycol Lozianeratide Injection (brand name: Fulaimi®) is the first innovative drug launched through the proprietary polyethylene glycol modification technology independently developed by Hansoh Pharmaceutical Group Company Limited. It is China's first domestically developed GLP-1RA weekly formulation, used for patients with BMI ≥25 who have inadequate glycemic control with oral hypoglycemic agents such as metformin or insulin.

In addition, the innovative drugs Pemostim Injection (brand name: Shengluolai®) and Aimitenovir Tablets (brand name: Hengmu®) have been included in the 2023 National Medical Insurance Catalog, and are still within the agreement period, valid until December 31, 2025. Morpholine Nitroimidazole Sodium Chloride Injection (brand name: Mailingda®) has been included in the Class B of the regular National Medical Insurance Catalog. All indications of the innovative drugs that have been launched by Hansoh Pharma are now covered by the medical insurance catalog, which will further enhance the affordability and accessibility of each innovative drug among patients.